Kuwait association of rheumatology 2018 treatment recommendations for patients with rheumatoid arthritis
- 121 Downloads
The Kuwait Association of Rheumatology (KAR) aimed to develop a set of recommendations for the treatment of patients with rheumatoid arthritis (RA), tailored to the unique patient population and healthcare system of Kuwait. Each recommendation was developed based on expert opinion and evaluation of clinical practice guidelines from other international and national rheumatology societies. Online surveys were conducted to collate feedback on each KAR member’s level of agreement (LoA) with definitions of disease-/treatment-related terms used and the draft recommendations. Definitions/recommendations achieving a pre-defined cut-off value of ≥ 70% agreement were accepted for inclusion. Remaining statements were discussed and revised at a face-to-face meeting, with further modifications until consensus was reached. A final online survey was used to collect feedback on each KAR member’s LoA with the final set of recommendation statements on a scale of 0 (complete disagreement) to 10 (complete agreement). Group consensus was achieved on 66 recommendation statements, including 3 overarching principles addressing the pharmacological treatment and management of RA. Recommendations focused on treatment of early RA, established RA, patients with high-risk comorbidities, women during pregnancy and breastfeeding, and screening and treatment of opportunistic infections. The KAR 2018 Treatment Recommendations for RA reported here are based on a synthesis of other national/international guidelines, supporting literature, and expert consensus considering the Kuwaiti healthcare system and RA patient population. These recommendations aim to inform the clinical decisions of rheumatologists treating patients in Kuwait, and to promote best practices, enhance alignment and improve the treatment experience for patients.
KeywordsDMARDs (biologic) DMARDs (synthetic) Tumor necrosis factor-alpha Anti-TNF Early rheumatoid arthritis Rheumatoid arthritis Pregnancy Infections Treatment
The authors thank Peter C. Taylor, MA, PhD, FRCP, FRCPE, for his independent review of the KAR 2018 Recommendations for RA. The authors also acknowledge Hinal Tanna, PhD, and Debbie Nixon, DPhil from Costello Medical, Cambridge, UK, for facilitating the recommendations meeting and surveys, and for medical writing and editorial assistance in preparing this manuscript for publication, based on the authors’ input and direction.
HA, FA, WAA, AAA, AA, AAE, NA, AAH, WA, AD, AAMG, EH, SH, KS, HT, and YA contributed to the conception, design, acquisition or analysis, and interpretation of the data. All authors approved the final version to be published after critically revising the manuscript for important intellectual content.
The KAR received unrestricted funds for the development of the KAR 2018 treatment recommendations for patients with RA from Eli Lilly, NewBridge Pharmaceuticals, Roche, and Pfizer.
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interest.
- 5.Gerhold K, Richter A, Schneider M, Bergerhausen H-J, Demary W, Liebhaber A et al (2015) Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT. Rheumatology 54(10):1858–1866. https://doi.org/10.1093/rheumatology/kev194 CrossRefPubMedGoogle Scholar
- 7.Goekoop-Ruiterman YM, de Vries-Bouwstra JK, Allaart CF et al (2007) Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146(6):406–415. https://doi.org/10.7326/0003-4819-146-6-200703200-00005 CrossRefPubMedGoogle Scholar
- 9.Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I et al (2002) Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology 41(12):1346–1356. https://doi.org/10.1093/rheumatology/41.12.1346 CrossRefPubMedGoogle Scholar
- 14.Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM et al (2012) 2012 Update of the 2008 American College of Rheumatology (ACR) recommendations for the use of disease-modifying anti-rheumatic drugs and biologics in the treatment of rheumatoid arthritis (RA). Arthritis Care Res 64(5):625–639. https://doi.org/10.1002/acr.21641 CrossRefGoogle Scholar
- 17.Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960–977. https://doi.org/10.1136/annrheumdis-2016-210715 CrossRefGoogle Scholar
- 18.Gotestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75(5):795–810. https://doi.org/10.1136/annrheumdis-2015-208840 CrossRefPubMedGoogle Scholar
- 19.Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B et al (2012) Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 39(8):1559–1582. https://doi.org/10.3899/jrheum.110207 CrossRefPubMedGoogle Scholar
- 21.Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K et al (2016) BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology 55(9):1693–1697. https://doi.org/10.1093/rheumatology/kev404 CrossRefPubMedGoogle Scholar
- 22.World Population Review (2018) Kuwait population 2018. https://Worldpopulationreview.Com/Countries/Kuwait-Population/. Accessed 10 Jan 2019
- 23.The Public Authority for Civil Information (2015) Kuwait stat app for statistical services. Statistical Services System. https://www.paci.gov.kw/stat/default.aspx. Accessed 23 Oct 2018
- 24.World Health Organization (2018) Global tuberculosis report 2018. https://www.who.int/tb/publications/global_report/en/. Accessed 23 Oct 2018
- 26.de Jong PH, Hazes JM, Barendregt PJ, Huisman M, van Zeben D, van der Lubbe PA et al (2012) Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis 72(1):72–78. https://doi.org/10.1136/annrheumdis-2011-201162 CrossRefPubMedGoogle Scholar
- 31.Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P et al (2017) Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 76(7):1253–62. https://doi.org/10.1136/annrheumdis-2016-210457Google Scholar
- 32.Keystone EC, Genovese MC, Schlichting DE, de la Torre I, Beattie SD, Rooney TP et al (2018) Safety and efficacy of baricitinib through 128 weeks in an open-label, long-term extension study in patients with rheumatoid arthritis. J Rheumatol 45(1):14–21. https://doi.org/10.3899/jrheum.161161 CrossRefPubMedGoogle Scholar
- 33.Burmester G-R, Kivitz AJ, Kupper H, Arulmani U, Florentinus S, Goss SL et al (2015) Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised concerto trial. Ann Rheum Dis 74(6):1037–1044. https://doi.org/10.1136/annrheumdis-2013-204769 CrossRefPubMedGoogle Scholar
- 34.Martinez-Feito A, Plasencia-Rodriguez C, Navarro-Compan V, Hernandez-Breijo B, Gonzalez MA, Monjo I et al (2019) The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. Clin Rheumatol 38(3):949–954. https://doi.org/10.1007/s10067-018-4355-0 CrossRefPubMedGoogle Scholar
- 35.Karlsson JA, Kristensen LE, Kapetanovic MC, Gülfe A, Saxne T, Geborek P (2008) Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 47(4):507–513. https://doi.org/10.1093/rheumatology/ken034 CrossRefPubMedGoogle Scholar
- 37.van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D et al (2009) Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 60(8):2262–2271. https://doi.org/10.1002/art.24661 CrossRefPubMedGoogle Scholar
- 44.Bombardier C, Hazlewood GS, Akhavan P, Schieir O, Dooley A, Haraoui B et al (2012) Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: Part II Safety. J Rheumatol 39(8):1583–1602. https://doi.org/10.3899/jrheum.120165 CrossRefPubMedGoogle Scholar
- 45.Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K (2010) Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection—United States, 2010. MMWR recommendations and reports: morbidity and mortality weekly report 59(RR-5):1-25Google Scholar
- 49.Lok ASF, Ward JW, Perrillo RP, McMahon BJ, Liang TJ (2012) Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med 156(10):743–745. https://doi.org/10.1059/0003-4819-156-10-201205150-00013 CrossRefPubMedPubMedCentralGoogle Scholar
- 51.Burton MJ, Curtis JR, Yang S, Chen L, Singh JA, Mikuls TR et al (2015) Safety of biologic and non-biologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study. Arthritis Res Ther 17(1):136. https://doi.org/10.1186/s13075-015-0628-z CrossRefPubMedPubMedCentralGoogle Scholar
- 53.Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY et al (2011) Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 70(10):1719–1725. https://doi.org/10.1136/ard.2010.148783 CrossRefPubMedGoogle Scholar
- 54.Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT (2015) American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148(1):215–219. https://doi.org/10.1053/j.gastro.2014.10.039 CrossRefPubMedGoogle Scholar
- 56.Zechini B, Pasquazzi C, Aceti A (2004) Correlation of serum aminotransferases with HCV RNA levels and histological findings in patients with chronic hepatitis C: the role of serum aspartate transaminase in the evaluation of disease progression. Eur J Gastroenterol Hepatol 16(9):891–896CrossRefGoogle Scholar
- 62.Al-Herz ASK, Al-Awadhi A, Al-Kandari W, Hasan E, Ghanem A, Ali Y et al (2018) Easy accessibility of biologics and its impact on disease activity and quality of life in Kuwaiti patients with rheumatoid arthritis [Abstract]. Arthritis Rheumatol 70(Suppl 9):624Google Scholar